Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Liabilities and Shareholders Equity (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $175.4 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 44.03% to $175.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $864.9 million through Dec 2025, down 39.83% year-over-year, with the annual reading at $175.4 million for FY2025, 44.03% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $175.4 million at Caribou Biosciences, down from $195.0 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $462.0 million in Q3 2021, with the low at $158.4 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $346.9 million, with a median of $372.9 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity surged 1127.2% in 2021, then tumbled 44.03% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $442.4 million in 2021, then fell by 15.51% to $373.8 million in 2022, then increased by 15.64% to $432.2 million in 2023, then fell by 27.51% to $313.3 million in 2024, then crashed by 44.03% to $175.4 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $175.4 million, $195.0 million, and $220.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.